Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

MedPal AI Plc (LSE:MPAL) Retreats as Investors Weigh Rapid Growth Against Funding and Dilution QuestionsCategory: Healthcare

MedPal AI is an AIM-quoted digital health and pharmacy group combining AI-driven health tools with regulated prescription dispensing. It operates NHS distance selling pharmacy hubs, an online pharmacy brand, a weight management clinic and care home pharmacy services. The 10.94% decline on 20 October, …

Ankur Sharma | 20 October 2026

RUA Life Sciences Plc (LSE:RUA) Pulls Back as Investors Await Evidence of Second-Half ProfitabilityCategory: Healthcare

RUA Life Sciences is a medical device contract development and manufacturing organisation specialising in implantable textiles and the Elast-Eon biostable polymer. It also licenses its polymer technology to device makers. The 9.90% decline on 20 October, 2026 follows a substantial rise in the shares …

Ankur Sharma | 20 October 2026

Ondine Biomedical, Inc. (LSE:OBI): Photodisinfection Developer Jumps as Infection Prevention Adoption Is Watched

Ondine Biomedical develops photodisinfection therapies that use light-activated agents to kill pathogens. Its Steriwave nasal treatment aims to reduce infections in surgical patients.

Ankur Sharma | 20 October 2026

Bioventix Plc (LSE:BVXP): Antibody Specialist Rises as Royalty Income and New Diagnostic Tests Are Watched

Bioventix develops and supplies sheep monoclonal antibodies used in blood tests run on large automated analysers in hospital and clinical laboratories. Its customers are major diagnostic companies that pay royalties on test sales.

Ankur Sharma | 20 October 2026

Creo Medical Group Plc (CREO): What FTSE and AIM Investors Should Watch Next

Creo Medical Group Plc (LSE:CREO) is relevant to investors tracking UK-listed shares because its valuation depends on a combination of company execution, sector conditions and the market’s expectations for future cash generation. The most useful way to assess the stock on 20 October 2026 …

Ankur Sharma | 20 October 2026

Shield Therapeutics Plc (STX): What FTSE and AIM Investors Should Watch Next

Shield Therapeutics Plc (LSE:STX) is relevant to investors tracking UK-listed shares because its valuation depends on a combination of company execution, sector conditions and the market’s expectations for future cash generation. The most useful way to assess the stock on 20 October 2026 is …

Ankur Sharma | 20 October 2026

Optima Health (LSE:OPT) in Focus on 20 October 2026: 60% First-Half Revenue Growth And Improving Contract Momentum Reshapes Investor Watchlist

Expected first-half revenue is approximately £96 million; annualised new business wins reached £10.6 million and net debt excluding leases declined to £70.4 million.

Ankur Sharma | 20 October 2026

IXICO (LSE:IXI) in Focus on 20 October 2026: A Fresh Trading Update And Clinical-Data Services Outlook Reshapes Investor Watchlist

The company issued a trading update on 20 October; precise financial figures require confirmation from the full statement.

Ankur Sharma | 20 October 2026

Ondine Biomedical (LSE:OBI) in Focus on 20 October 2026: Fundraising Outcome And Restoration Of Trading Reshapes Investor Watchlist

The company announced the result of a fundraise and restoration of trading on 20 October; the final issuance terms and share count merit checking.

Ankur Sharma | 20 October 2026

Physiomics (LSE:PYC) in Focus on 20 October 2026: New Contract Award And Drug-Development Modelling Demand Reshapes Investor Watchlist

The company recently disclosed a £119,000 modelling contract and exploration of additional commercial opportunities.

Ankur Sharma | 20 October 2026
Support

Hi! How can we help you today?

Loading…